We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Proton Therapy Has Better Outcome over IMRT for Advanced Head and Neck Cancers

By HospiMedica International staff writers
Posted on 21 Jul 2014
Radiation oncologists compared the world’s literature on outcomes of proton beam therapy in the treatment of a range of advanced head and neck cancers of the skull base compared to intensity-modulated radiation therapy (IMRT) and found that proton beam therapy significantly improved disease-free survival and tumor control when compared to IMRT. More...


The study’s findings were published June 27, 2014, in the journal Lancet Oncology. “We undertook a systematic review and meta-analysis to compare the clinical outcomes of patients treated with proton therapy with patients receiving photon IMRT,” said senior author Robert Foote, MD, a radiation oncologist at the Mayo Clinic (Rochester, MN, USA). “Our findings suggest that the theoretical advantages of proton beam therapy may in fact be real.”

Researchers reviewed cases of nasal cavity and paranasal sinus tumors through extensive database searches. They included studies of patients who had no earlier treatment—neither primary radiation therapy nor adjuvant radiation therapy—and patients who had recurrent disease. Researchers collected data on overall survival, disease-free survival, and tumor control, at five years and at the patient’s longest follow-up. They used random-effect models to pool outcomes across studies and compared event rates of combined outcomes for proton therapy and IMRT using an interaction test.

Researchers discovered disease-free survival to be significantly higher at five years for patients receiving proton therapy than for patients receiving IMRT (72% versus 50%). Tumor control did not differ between treatment groups at five years however tumor control was higher for patients receiving proton therapy than for IMRT at the longest follow-up (81% versus 64%).


Related Links:

Mayo Clinic



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Glucose Meter
StatStrip®
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Masimo smartSET pulse oximetry with PPG AFib and OIRD Detection (Photo courtesy of Masimo)

Smart Pulse Oximetry Supports Earlier Recognition of Arrhythmias and Respiratory Risk

On general care floors, respiratory compromise and arrhythmias can develop between routine checks. Atrial fibrillation often goes undiagnosed in older adults, while opioid-induced respiratory depression... Read more

Surgical Techniques

view channel
Image: A UTSW clinical trial studied a treatment strategy for kidney cancer with inferior vena cava tumor thrombus (IVC-TT) that used targeted radiation on the tumor thrombus followed by surgery to remove the kidney. (Photo courtesy of UT Southwestern)

Targeted Radiotherapy Before Surgery Improves Control of Kidney Cancer Thrombus

Inferior vena cava tumor thrombus occurs when kidney cancer extends into the body’s largest vein, potentially obstructing blood flow, progressing toward the heart, and making surgery more complex.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.